You don't know that we'll get there.
OTC doesn't reward profitable/growing companies. OTC doesn't provide support/liquidity because the lack of institutional investors. So chances are, only a small percent of investors will see the actual value in the company and most retail isn't going to pony up the amount of $$ to offset the selling, like we have already seen.
Everyone got mad that shares may have been offered to get some eyes on KAVL, and now you think retail is just going to buy us up to $4.00 through word of mouth? If re-affirming $400M revenues for 2021, new distribution contracts, expansion to new markets, a new product, etc isn't going to get us the "hype" we need to get up to $4, then what will?